IP Library Granted Patent US 9,029,144
Granted Patent B2
US 9,029,144 · App. 12/485,575 · Granted May 12, 2015

Methods for enhanced propagation of cells

Inventors: Mark Szczypka (Ann Arbor, MI); Evangelos Tziampazis (East Lyme, CT); Angela J. Westover (Ann Arbor, MI)
Assignees: Innovative Bio Therapies, Inc.; CytoPherx, Inc.
C12N5/0687C12N2501/385
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,029,144
App. No.
12/485,575
Granted
May 12, 2015
Kind
B2
Abstract

The present invention relates generally to methods for the isolation and propagation of cells. For example, embodiments of the present invention relate to isolation and propagation methods for the manufacture of a large number of cells for use, for example, in biotherapeutic devices, such as devices for renal replacement therapy for the treatment of acute renal failure (ARF), acute tubular necrosis (ATN), multi-organ failure (MOF), sepsis, cardiorenal syndrome (CRS) and end-stage renal disease (ESRD).

Claims (31)

1. A method for enhanced propagation of cells from a kidney sample, the method comprising culturing renal precursor cells from the sample while retaining non-adherent cells when culture or subculture growth medium is changed, thereby to enhance propagation of a cell population from the sample.

2. The method of claim 1 , wherein the method maintains the precursor cells in an undifferentiated state.

3. The method of claim 1 , wherein the method increases the number of precursor cells relative to the number present in the sample.

4. The method of claim 1 , wherein the method comprises dilution of cells in the sample.

5. The method of claim 1 , wherein the enhanced propagation cell population comprises renal cells.

6. The method of claim 1 , further comprising administering retinoic acid.

7. The method of claim 1 , the method comprising applying conditions that stimulate precursor cells.

8. The method of claim 1 , the method comprising applying conditions that amplify precursor cells.

9. A method for propagating renal cells from a kidney sample, the method comprising:

(a) treating the kidney sample to produce tissue fragments having a dimension of about 212 μm or less in size;

(b) harvesting at least a portion of the tissue fragments by centrifugation at greater than 200×(g) to produce a pelleted slurry;

(c) applying a portion of the pelleted slurry produced in step (b) to a solid support and culturing the cells from the pelleted slurry in the absence of retinoic acid and under conditions to permit the renal cells to attach to the solid support and divide;

(d) harvesting the cells produced in step (c) prior to reaching confluence on the solid support;

(e) applying a portion of the cells harvested in step (d) to a solid support and subculturing the cells in the absence of retinoic acid and under conditions to permit the renal cells to attach to the solid support and divide; and

(f) harvesting the cells produced in step (e) to produce a propagated population of renal cells.

10. The method of claim 9 , wherein non-adherent cells are retained when culture or subculture growth medium is changed.

11. A method for enhanced propagation of cells from a kidney sample, the method comprising:

separating the kidney sample into fragments of about 212 μm or less in size to produce a slurry;

centrifuging the slurry at greater than 200×(g) to produce a pelleted slurry;

creating a culture by applying to a growth surface about 10 μl or less of the pelleted slurry per square centimeter of surface area on which the culture is to be grown, wherein said 10 μl or less of the pelleted slurry is resuspended in a sufficient amount of a culture medium for plating; and

subculturing about 8.7×10 4 or fewer cells from the culture per square centimeter of surface area on which the subculture is to be grown.

12. The method of claim 11 , further comprising adding retinoic acid after the subculturing step.

13. The method of claim 11 , wherein non-adherent cells are retained when culture or subculture growth medium is changed.

14. The method of claim 11 , wherein the subculturing step occurs prior to confluence.

15. The method of claim 11 , further comprising subculturing about 8.7×10 4 or fewer cells from the subculture per square centimeter of surface area on which the further subculture is to be grown.

16. The method of claim 9 , wherein step (e) further comprises permitting the cells to divide until confluence.

17. The method of claim 16 , wherein step (f) further comprises seeding harvested cells onto a solid support.

18. The method of claim 17 , further comprising adding retinoic acid to the cells seeded onto the solid support and permitting the cells to differentiate.

19. The method of claim 9 , wherein after step (f), the cell yield is at least 3.22×10 10 renal epithelial cells per gram of kidney cortex tissue.

20. The method of claim 9 , wherein the kidney sample is an adult kidney sample.

21. The method of claim 11 , wherein the kidney sample is an adult kidney sample.

Assignments (12)
CHANGE OF NAME Recorded Apr 4, 2022
From: NEPHROS THERAPEUTICS, INC.
To: RENAMED BIOLOGICS, INC.
Reel/Frame 059593/0191 →
CHANGE OF NAME Recorded Apr 4, 2022
From: NEPHRION, INC.
To: CYTOPHERX, INC.
Reel/Frame 059593/0221 →
ASSET PURCHASE AGREEMENT Recorded Apr 4, 2022
From: RENAMED BIOLOGICS, INC.
To: NEPHRION, INC.
Reel/Frame 059593/0224 →
CHANGE OF NAME Recorded Apr 4, 2022
From: CYTOPHERX, INC.
To: SEASTAR MEDICAL, INC.
Reel/Frame 059593/0257 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2022
From: TZIAMPAZIS, EVANGELOS
To: NEPHROS THERAPEUTICS, INC.
Reel/Frame 059492/0915 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2022
From: INNOVATIVE BIOTHERAPIES, INC.
To: SEASTAR MEDICAL, INC.
Reel/Frame 059493/0413 →
CONFIRMATORY LICENSE Recorded Jul 16, 2014
From: INNOVATIVE BIOTHERAPIES, INC.
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 033338/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2010
From: SZCZYPKA, MARK
To: CYTOPHERX, INC.
Reel/Frame 024478/0384 →
CONFIRMATORY LICENSE Recorded May 13, 2010
From: INNOVATIVE BIOTHERAPIES, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024379/0454 →
CHANGE OF NAME Recorded Dec 2, 2009
From: NEPHRION, INC.
To: CYTOPHERX, INC.
Reel/Frame 023592/0635 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2009
From: WESTOVER, ANGELA J.
To: NEPHRION, INC.
Reel/Frame 023384/0080 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2009
From: WESTOVER, ANGELA J.
To: INNOVATIVE BIOTHERAPIES, INC.
Reel/Frame 023384/0113 →
Continuity (2)
Provisional Application 61073745 · Jun 18, 2008
Related Publication 20100136687A1 · Jun 3, 2010